182 related articles for article (PubMed ID: 38181441)
41. Biomimetic cell membrane-coated nanocarriers for targeted siRNA delivery in cancer therapy.
Huang X; Guo H; Wang L; Zhang Z; Zhang W
Drug Discov Today; 2023 Apr; 28(4):103514. PubMed ID: 36736580
[TBL] [Abstract][Full Text] [Related]
42. siRNA-based nanotherapeutics as emerging modalities for immune-mediated diseases: A preliminary review.
Sargazi S; Arshad R; Ghamari R; Rahdar A; Bakhshi A; Karkan SF; Ajalli N; Bilal M; Díez-Pascual AM
Cell Biol Int; 2022 Sep; 46(9):1320-1344. PubMed ID: 35830711
[TBL] [Abstract][Full Text] [Related]
43. Nano-scale delivery systems for siRNA delivery in cancer therapy: New era of gene therapy empowered by nanotechnology.
Ebrahimi N; Manavi MS; Nazari A; Momayezi A; Faghihkhorasani F; Rasool Riyadh Abdulwahid AH; Rezaei-Tazangi F; Kavei M; Rezaei R; Mobarak H; Aref AR; Fang W
Environ Res; 2023 Dec; 239(Pt 2):117263. PubMed ID: 37797672
[TBL] [Abstract][Full Text] [Related]
44. Theranostic Nanoparticles for RNA-Based Cancer Treatment.
Revia RA; Stephen ZR; Zhang M
Acc Chem Res; 2019 Jun; 52(6):1496-1506. PubMed ID: 31135134
[TBL] [Abstract][Full Text] [Related]
45. Tumor-targeting delivery of herb-based drugs with cell-penetrating/tumor-targeting peptide-modified nanocarriers.
Kebebe D; Liu Y; Wu Y; Vilakhamxay M; Liu Z; Li J
Int J Nanomedicine; 2018; 13():1425-1442. PubMed ID: 29563797
[TBL] [Abstract][Full Text] [Related]
46. Dual Targeted Nanoparticles for the Codelivery of Doxorubicin and siRNA Cocktails to Overcome Ovarian Cancer Stem Cells.
Chen L; Luo J; Zhang J; Wang S; Sun Y; Liu Q; Cheng C
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511335
[TBL] [Abstract][Full Text] [Related]
47. Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.
Draz MS; Fang BA; Zhang P; Hu Z; Gu S; Weng KC; Gray JW; Chen FF
Theranostics; 2014; 4(9):872-92. PubMed ID: 25057313
[TBL] [Abstract][Full Text] [Related]
48. Recent Progress in Delivery of Therapeutic and Imaging Agents Utilizing Organic-Inorganic Hybrid Nanoparticles.
Haque ST; Chowdhury EH
Curr Drug Deliv; 2018; 15(4):485-496. PubMed ID: 29165073
[TBL] [Abstract][Full Text] [Related]
49. Delivering siRNA with Dendrimers: In Vivo Applications.
Leiro V; Santos SD; Pego AP
Curr Gene Ther; 2017; 17(2):105-119. PubMed ID: 28494741
[TBL] [Abstract][Full Text] [Related]
50. Nanocarriers: a tool to overcome biological barriers in siRNA delivery.
Kumari A; Kumar V; Yadav SK
Expert Opin Biol Ther; 2011 Oct; 11(10):1327-39. PubMed ID: 21682658
[TBL] [Abstract][Full Text] [Related]
51. Facile Hydrophobization of siRNA with Anticancer Drug for Non-Cationic Nanocarrier-Mediated Systemic Delivery.
Xu C; Li D; Cao Z; Xiong M; Yang X; Wang J
Nano Lett; 2019 Apr; 19(4):2688-2693. PubMed ID: 30844291
[TBL] [Abstract][Full Text] [Related]
52. An updated review of folate-functionalized nanocarriers: A promising ligand in cancer.
Ebrahimnejad P; Sodagar Taleghani A; Asare-Addo K; Nokhodchi A
Drug Discov Today; 2022 Feb; 27(2):471-489. PubMed ID: 34781032
[TBL] [Abstract][Full Text] [Related]
53. Mechanisms and challenges of nanocarriers as non-viral vectors of therapeutic genes for enhanced pulmonary delivery.
Wang H; Qin L; Zhang X; Guan J; Mao S
J Control Release; 2022 Dec; 352():970-993. PubMed ID: 36372386
[TBL] [Abstract][Full Text] [Related]
54. Polyethylenimines for RNAi-mediated gene targeting in vivo and siRNA delivery to the lung.
Günther M; Lipka J; Malek A; Gutsch D; Kreyling W; Aigner A
Eur J Pharm Biopharm; 2011 Apr; 77(3):438-49. PubMed ID: 21093588
[TBL] [Abstract][Full Text] [Related]
55. Preparation and in-vitro evaluation of mesoporous biogenic silica nanoparticles obtained from rice and wheat husk as a biocompatible carrier for anti-cancer drug delivery.
Porrang S; Rahemi N; Davaran S; Mahdavi M; Hassanzadeh B
Eur J Pharm Sci; 2021 Aug; 163():105866. PubMed ID: 33957220
[TBL] [Abstract][Full Text] [Related]
56. Multifunctional nanoparticles delivering small interfering RNA and doxorubicin overcome drug resistance in cancer.
Chen Y; Bathula SR; Li J; Huang L
J Biol Chem; 2010 Jul; 285(29):22639-50. PubMed ID: 20460382
[TBL] [Abstract][Full Text] [Related]
57. Nanocarriers for delivery of siRNA and co-delivery of siRNA and other therapeutic agents.
Zhao J; Feng SS
Nanomedicine (Lond); 2015 Jul; 10(14):2199-228. PubMed ID: 26214357
[TBL] [Abstract][Full Text] [Related]
58. Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect
Li F; Wang Y; Chen WL; Wang DD; Zhou YJ; You BG; Liu Y; Qu CX; Yang SD; Chen MT; Zhang XN
Theranostics; 2019; 9(20):5886-5898. PubMed ID: 31534526
[TBL] [Abstract][Full Text] [Related]
59. A Review on Recent Technologies and Patents on Silica Nanoparticles for Cancer Treatment and Diagnosis.
Gupta A; Kushwaha SS; Mishra A
Recent Pat Drug Deliv Formul; 2020; 14(2):126-144. PubMed ID: 32928094
[TBL] [Abstract][Full Text] [Related]
60. VEGF siRNA Delivery by a Cancer-Specific Cell-Penetrating Peptide.
Lee YW; Hwang YE; Lee JY; Sohn JH; Sung BH; Kim SC
J Microbiol Biotechnol; 2018 Mar; 28(3):367-374. PubMed ID: 29316746
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
